Your browser doesn't support javascript.
loading
Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors.
Baart, Victor M; van Manen, Labrinus; Bhairosingh, Shadhvi S; Vuijk, Floris A; Iamele, Luisa; de Jonge, Hugo; Scotti, Claudia; Resnati, Massimo; Cordfunke, Robert A; Kuppen, Peter J K; Mazar, Andrew P; Burggraaf, Jacobus; Vahrmeijer, Alexander L; Sier, Cornelis F M.
Afiliação
  • Baart VM; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. V.M.Baart@lumc.nl.
  • van Manen L; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
  • Bhairosingh SS; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
  • Vuijk FA; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
  • Iamele L; Unit of Immunology and General Pathology, Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • de Jonge H; Ardis Srl, Pavia, Italy.
  • Scotti C; Unit of Immunology and General Pathology, Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Resnati M; Ardis Srl, Pavia, Italy.
  • Cordfunke RA; Unit of Immunology and General Pathology, Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Kuppen PJK; Ardis Srl, Pavia, Italy.
  • Mazar AP; Age Related Diseases Unit, Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy.
  • Burggraaf J; Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
  • Vahrmeijer AL; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
  • Sier CFM; Monopar Therapeutics, Wilmette, IL, USA.
Mol Imaging Biol ; 25(1): 122-132, 2023 02.
Article em En | MEDLINE | ID: mdl-34642899
ABSTRACT

PURPOSE:

Radical resection is paramount for curative oncological surgery. Fluorescence-guided surgery (FGS) aids in intraoperative identification of tumor-positive resection margins. This study aims to assess the feasibility of urokinase plasminogen activator receptor (uPAR) targeting antibody fragments for FGS in a direct comparison with their parent IgG in various relevant in vivo models. PROCEDURES Humanized anti-uPAR monoclonal antibody MNPR-101 (uIgG) was proteolytically digested into F(ab')2 and Fab fragments named uFab2 and uFab. Surface plasmon resonance (SPR) and cell assays were used to determine in vitro binding before and after fluorescent labeling with IRDye800CW. Mice bearing subcutaneous HT-29 human colonic cancer cells were imaged serially for up to 120 h after fluorescent tracer administration. Imaging characteristics and ex vivo organ biodistribution were further compared in orthotopic pancreatic ductal adenocarcinoma (BxPc-3-luc2), head-and-neck squamous cell carcinoma (OSC-19-luc2-GFP), and peritoneal carcinomatosis (HT29-luc2) models using the clinical Artemis fluorescence imaging system.

RESULTS:

Unconjugated and conjugated uIgG, uFab2, and uFab specifically recognized uPAR in the nanomolar range as determined by SPR and cell assays. Subcutaneous tumors were clearly identifiable with tumor-to-background ratios (TBRs) > 2 after 72 h for uIgG-800F and 24 h for uFab2-800F and uFab-800F. For the latter two, mean fluorescence intensities (MFIs) dipped below predetermined threshold after 72 h and 36 h, respectively. Tumors were easily identified in the orthotopic models with uIgG-800F consistently having the highest MFIs and uFab2-800F and uFab-800F having similar values. In biodistribution studies, kidney and liver fluorescence approached tumor fluorescence after uIgG-800F administration and surpassed tumor fluorescence after uFab2-800F or uFab-800F administration, resulting in interference in the abdominal orthotopic mouse models.

CONCLUSIONS:

In a side-by-side comparison, FGS with uPAR-targeting antibody fragments compared with the parent IgG resulted in earlier tumor visualization at the expense of peak fluorescence intensity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Receptores de Ativador de Plasminogênio Tipo Uroquinase Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Receptores de Ativador de Plasminogênio Tipo Uroquinase Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article